MX2019004766A - Metodos, composiciones y regimenes de dosificacion para tratar o prevenir indicaciones relacionadas con interferon-gamma. - Google Patents
Metodos, composiciones y regimenes de dosificacion para tratar o prevenir indicaciones relacionadas con interferon-gamma.Info
- Publication number
- MX2019004766A MX2019004766A MX2019004766A MX2019004766A MX2019004766A MX 2019004766 A MX2019004766 A MX 2019004766A MX 2019004766 A MX2019004766 A MX 2019004766A MX 2019004766 A MX2019004766 A MX 2019004766A MX 2019004766 A MX2019004766 A MX 2019004766A
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- methods
- interferon
- gamma
- treat
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/249—Interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Pathology (AREA)
- Mycology (AREA)
- Transplantation (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- General Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662411783P | 2016-10-24 | 2016-10-24 | |
| PCT/IB2017/001427 WO2018078442A2 (en) | 2016-10-24 | 2017-10-24 | Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019004766A true MX2019004766A (es) | 2019-09-27 |
Family
ID=60957345
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019004766A MX2019004766A (es) | 2016-10-24 | 2017-10-24 | Metodos, composiciones y regimenes de dosificacion para tratar o prevenir indicaciones relacionadas con interferon-gamma. |
| MX2025012950A MX2025012950A (es) | 2016-10-24 | 2019-04-24 | Composiciones para usarse en el tratamiento de indicaciones relacionadas con interferon-gamma |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2025012950A MX2025012950A (es) | 2016-10-24 | 2019-04-24 | Composiciones para usarse en el tratamiento de indicaciones relacionadas con interferon-gamma |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP3528845A2 (enExample) |
| JP (3) | JP2019532970A (enExample) |
| KR (2) | KR20190071785A (enExample) |
| CN (1) | CN110167593A (enExample) |
| AU (2) | AU2017352033A1 (enExample) |
| BR (1) | BR112019008156A2 (enExample) |
| CA (2) | CA3244670A1 (enExample) |
| EA (1) | EA201990930A1 (enExample) |
| IL (1) | IL266174B2 (enExample) |
| MX (2) | MX2019004766A (enExample) |
| SG (1) | SG11201903659WA (enExample) |
| WO (1) | WO2018078442A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11091543B2 (en) | 2015-05-07 | 2021-08-17 | Swedish Orphan Biovitrum Ag | Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications |
| JP2018515493A (ja) | 2015-05-07 | 2018-06-14 | ノビミューン エスアー | Ｃｘｃｌ９および他のバイオマーカーのレベルが上昇した患者における障害の診断および治療のための方法および組成物 |
| CN118165113B (zh) * | 2016-04-26 | 2025-10-28 | 恺兴生命科技(上海)有限公司 | 一种改善免疫应答细胞功能的方法 |
| EP3488851A1 (en) * | 2018-10-03 | 2019-05-29 | AVM Biotechnology, LLC | Immunoablative therapies |
| WO2021185832A1 (en) | 2020-03-16 | 2021-09-23 | Swedish Orphan Biovitrum Ag | New therapeutic treatment |
| US20230149465A1 (en) * | 2020-04-06 | 2023-05-18 | Celledit Llc | Genetically modified immune cells expressing a chimeric antigen receptor and having reduced proinflammatory cytokine signaling |
| EP4724095A1 (en) | 2023-06-09 | 2026-04-15 | Children's Hospital Medical Center | Treatment of stem cell graft failure |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| WO2000032634A1 (en) * | 1998-12-01 | 2000-06-08 | Protein Design Labs, Inc. | Humanized antibodies to gamma-interferon |
| US20030138417A1 (en) | 2001-11-08 | 2003-07-24 | Kaisheva Elizabet A. | Stable liquid pharmaceutical formulation of IgG antibodies |
| MX2007008719A (es) * | 2005-01-27 | 2007-09-11 | Novimmune Sa | Anticuerpos anti-interferon gamma y metodos de uso de los mismos. |
| AU2006247039B2 (en) | 2005-05-19 | 2011-03-03 | Amgen Inc. | Compositions and methods for increasing the stability of antibodies |
| WO2009080541A1 (en) | 2007-12-21 | 2009-07-02 | F. Hoffmann-La Roche Ag | Antibody formulation |
| SG11201402490XA (en) * | 2011-11-23 | 2014-06-27 | Amgen Inc | Methods of treatment using an antibody against interferon gamma |
| KR20170018810A (ko) | 2014-06-10 | 2017-02-20 | 메이지 세이카 파루마 가부시키가이샤 | 안정한 아달리무맙 수성 제제 |
| JP2018515493A (ja) * | 2015-05-07 | 2018-06-14 | ノビミューン エスアー | Ｃｘｃｌ９および他のバイオマーカーのレベルが上昇した患者における障害の診断および治療のための方法および組成物 |
-
2017
- 2017-10-24 BR BR112019008156-9A patent/BR112019008156A2/pt unknown
- 2017-10-24 KR KR1020197014837A patent/KR20190071785A/ko not_active Ceased
- 2017-10-24 CA CA3244670A patent/CA3244670A1/en active Pending
- 2017-10-24 JP JP2019521706A patent/JP2019532970A/ja not_active Withdrawn
- 2017-10-24 AU AU2017352033A patent/AU2017352033A1/en not_active Abandoned
- 2017-10-24 IL IL266174A patent/IL266174B2/en unknown
- 2017-10-24 KR KR1020247033365A patent/KR20240148970A/ko not_active Ceased
- 2017-10-24 CN CN201780080221.6A patent/CN110167593A/zh active Pending
- 2017-10-24 MX MX2019004766A patent/MX2019004766A/es unknown
- 2017-10-24 WO PCT/IB2017/001427 patent/WO2018078442A2/en not_active Ceased
- 2017-10-24 SG SG11201903659WA patent/SG11201903659WA/en unknown
- 2017-10-24 CA CA3041434A patent/CA3041434A1/en active Pending
- 2017-10-24 EA EA201990930A patent/EA201990930A1/ru unknown
- 2017-10-24 EP EP17829009.4A patent/EP3528845A2/en active Pending
-
2019
- 2019-04-24 MX MX2025012950A patent/MX2025012950A/es unknown
-
2022
- 2022-10-28 JP JP2022173528A patent/JP7562074B2/ja active Active
-
2024
- 2024-09-06 JP JP2024153940A patent/JP7891510B2/ja active Active
- 2024-11-12 AU AU2024264563A patent/AU2024264563A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019532970A (ja) | 2019-11-14 |
| EP3528845A2 (en) | 2019-08-28 |
| MX2025012950A (es) | 2025-12-01 |
| EA201990930A1 (ru) | 2019-11-29 |
| JP2024170569A (ja) | 2024-12-10 |
| AU2017352033A1 (en) | 2019-06-06 |
| WO2018078442A3 (en) | 2018-08-23 |
| JP2022187025A (ja) | 2022-12-15 |
| JP7891510B2 (ja) | 2026-07-16 |
| IL266174B1 (en) | 2024-06-01 |
| CA3244670A1 (en) | 2025-11-29 |
| JP7562074B2 (ja) | 2024-10-07 |
| AU2024264563A1 (en) | 2024-11-28 |
| SG11201903659WA (en) | 2019-05-30 |
| BR112019008156A2 (pt) | 2019-07-02 |
| CA3041434A1 (en) | 2018-05-03 |
| WO2018078442A2 (en) | 2018-05-03 |
| IL266174A (en) | 2019-06-30 |
| KR20190071785A (ko) | 2019-06-24 |
| KR20240148970A (ko) | 2024-10-11 |
| IL266174B2 (en) | 2024-10-01 |
| CN110167593A (zh) | 2019-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2025012950A (es) | Composiciones para usarse en el tratamiento de indicaciones relacionadas con interferon-gamma | |
| ECSP20058592A (es) | Composiciones y métodos para tratar anemia | |
| MX2021012155A (es) | Composiciones y metodos para el tratamiento de la anemia. | |
| MX2019003938A (es) | Compuestos espirociclicos. | |
| BR112018073329A2 (pt) | combinação, composição farmacêutica, kit, método para tratar câncer, método para reduzir um nível de células, método para aumentar a atividade, método para aumentar a citotoxicidade, método para reduzir metástase | |
| MX2021009899A (es) | Administracion y dosificacion de diaminofenotiazinas. | |
| BR112018008103A2 (pt) | análogos de celastrol | |
| MX2017014191A (es) | Metodos de tratamiento de una enfermedad neurodegenerativa. | |
| BR112017005598A2 (pt) | macrociclos peptidomiméticos e usos dos mesmos | |
| NI201900096A (es) | Moduladores de la expresión de pcsk9 | |
| BR112017024163A2 (pt) | compostos bicíclicos | |
| BR112019001039A2 (pt) | composição para uso no tratamento de transtorno depressivo maior | |
| MX2019013808A (es) | Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer. | |
| TW201713333A (en) | Methods of treating a neurodegenerative disease | |
| MX2017012553A (es) | Compuestos espirociclicos. | |
| EA201791933A1 (ru) | Ингибирование активности olig2 | |
| EA201691896A1 (ru) | Соединения и способы их применения | |
| BR112019006504A2 (pt) | regime de dosagem de avelumabe para o tratamento de câncer | |
| PH12017501897A1 (en) | 2-thiopyrimidinones | |
| MX2016014780A (es) | Metodos y composiciones de dasotralina para el tratamiento del adhd. | |
| BR112017017594A2 (pt) | dosagens de panobinostat para mieloma múltiplo | |
| MX2016014768A (es) | Dosificacion de dasotralina y metodo para el tratamiento del trastorno por deficit de atencion con hiperactividad adhd. | |
| PH12018501570A1 (en) | Pharmaceutical composition for preventing or treating diabetic nephropathy | |
| HK40012444A (en) | Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications | |
| BR112017006190A2 (pt) | agentes terapêuticos humanos |